We are monitoring the impact of COVID-19 on Alzheimer's Disease (AD) Diagnostics And Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date August, 2019
ID: 2153
Share on
Share on

Global Alzheimer's Disease (AD) Diagnostics And Therapeutics Market Size, Share, Trends, Growth Analysis Report - Segmented By Therapeutics (Marketed Drugs-(NMDA Receptor Antagonists, Cholinesterase Inhibitors), Pipeline Drugs), By Diagnostics (Computed Tomography Scan, Electroencephalography, Lumbar Puncture Test, Magnetic Resonance Imaging, Positron Emission Tomography, And Others), By Region - Industry Forecast | 2019 to 2024

Pulished: August, 2019
ID: 2153
Pages: 178

Industry Analysis

The size of the global Alzheimer's disease therapeutics and diagnostics market was worth USD 11288.5 Million in 2018 and estimated to be growing at a CAGR of 4.67%, to reach USD 14179.7 Million from the forecast period 2019 to 2024.

Alzheimer's disease (AD) is the most natural cause of progressive dementia in the elderly populace. There has been an exponential increase in the frequency of Alzheimer's disease cases globally, stressing the need to develop an effective treatment to cure it.

Alzheimer's disease (AD) is one of the most widespread dementia in the world. According to the facts and figures of Alzheimer's association, in every 33 seconds, a new case with Alzheimer's disease occurs, at a very high stage, there are millions of patients are suffering. Eventually, the improvement in the technology regarding AD and neurodegenerative conditions is becoming very important. 10-20% of the diagnosis of the AD is inaccurate to overcome this hurdle. Alzheimer's disease is a degenerative and progressive disease that attacks the nerve cells, which result in the loss of memory, behavioural changes and changes in thinking and language skills. There is fast growth in the people living with Alzheimer's disease around one individual in four diagnosed with this disease. 

MARKET DRIVERS

The growth of the global Alzheimer's disease therapeutics and diagnostics market is mainly driven by factors such as growing old age population, rising R&D investment, high frequency of Alzheimer's and neurodegenerative diseases, and improved life expectancy of the general population.

The other factors anticipated the growth of this market are increasing occurrence of chronic diseases like dementia, increasing channel drug development, and venture in biomarkers for drug development and increasing refined diagnostics for early detection and more specific drug development.

MARKET CHALLENGES

However, factors such as the astronomical cost of treatment and lack of proper reimbursement policies are preventing the growth of the market.

Presently, very few therapeutic options are present in the market, and none of them offers a complete remedy for this condition. Hence, entry into the market would provide lucrative growth prospects to the industry players.

REPORT COVERAGE

REPORT METRIC

DETAILS

Market Size Available

2018 – 2024

Base Year

2018

Forecast Period

2019 – 2024

Segments Analysed

By Therapeutics, Diagnostics and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Analysed

North America, Europe, Asia Pacific, Latin America, Middle East and Africa

 

This research report on the global Alzheimer's disease (ad) diagnostics and therapeutics market segmented and sub-segmented based on the Therapeutics, diagnostics and region.

Alzheimer's disease (AD) Diagnostics and Therapeutics Market – By Therapeutics

  • Marketed Drugs
    • NMDA Receptor Antagonists
    • Cholinesterase Inhibitors
  • Pipeline Drugs

The Marketed Drugs segment predicted to lead the global market based on Therapeutics due to a large user base.

Alzheimer's disease (AD) Diagnostics and Therapeutics Market – By Diagnostics

  • Computed tomography scan
  • Electroencephalography
  • Lumbar puncture test
  • Magnetic resonance imaging
  • Positron emission tomography
  • Others

Among all the segments, Computed tomography scan segment leads the global Alzheimer's disease (AD) Therapeutics and Diagnostics market. The absence of an alternative imaging tool for brain and neurological diagnostics is one of the crucial reasons for its large share.

Regional Analysis

North America is anticipated to be the largest market for Alzheimer's disease Therapeutics and Diagnostics due to the growing prevalence of Alzheimer's disease and extensive technological developments in the region. With the rise in the ageing populace in the developing area of Asia Pacific, this market is projected to grow at the highest CAGR during the forecast period.

Leading companies in the Global Alzheimer's Disease Therapeutics and Diagnostics Market analyzed in this report are Abbvie Inc., Pfizer Inc., AC Immune SA, Eisai Co Ltd., Allergan PLC, Novartis AG, Amarantus Bioscience Holdings, H. Lundbeck A/S, Anavex LifeSciences, Avid Radiopharmaceuticals, Forest Laboratories Inc., Axon Neuroscience, Daiichi Sankyo Co, TauRx Therapeutics Ltd, Eli Lilly, F. Hoffmann La Roche AG, Johnson & Johnson, GE Healthcare and Janssen Pharmaceuticals.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Therapeutics                              

                                5.1.1 Introduction           

                                5.1.2 Marketed Drugs   

                                                5.1.2.1 NMDA Receptor Antagonists

                                                5.1.2.2 Cholinesterase Inhibitors

                                5.1.3 Pipeline Drugs       

                                5.1.4  Y-o-Y Growth Analysis, By Therapeutics    

                                5.1.5  Market Attractiveness Analysis, By Therapeutics  

                                5.1.6  Market Share Analysis, By Therapeutics    

                5.2 Diagnostics                 

                                5.2.1 Introduction           

                                5.2.2 Computed tomography scan           

                                5.2.3 Electroencephalography   

                                5.2.4 Lumbar puncture test        

                                5.2.5 Magnetic resonance imaging          

                                5.2.6 Positron emission tomography      

                                5.2.7 Others      

                                5.2.8  Y-o-Y Growth Analysis, By Diagnostics        

                                5.2.9  Market Attractiveness Analysis, By Diagnostics      

                                5.2.10  Market Share Analysis, By Diagnostics     

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Therapeutics

                                                6.1.3.3 By Diagnostics

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Therapeutics

                                                6.1.4.3 By Diagnostics

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Therapeutics

                                                6.1.5.3 By Diagnostics

                6.2 North America                          

                                6.1.1 Introduction           

                                6.1.2 United States         

                                6.1.3 Canada     

                6.3 Europe                         

                                6.2.1 Introduction           

                                6.2.2 U.K             

                                6.2.3 Spain         

                                6.2.4 Germany 

                                6.2.5 Italy            

                                6.2.6 France       

                6.4 Asia-Pacific                 

                                6.3.1 Introduction           

                                6.3.2 China         

                                6.3.3 India          

                                6.3.4 Japan         

                                6.3.5 Australia   

                                6.3.6 South Korea           

                6.5 Latin America                             

                                6.4.1 Introduction           

                                6.4.2 Brazil          

                                6.4.3 Argentina

                                6.4.4 Mexico     

                                6.4.5 Rest of Latin America          

                6.6 Middle East & Africa                               

                                6.5.1 Introduction           

                                6.5.2 Middle-East            

                                6.5.3 Africa         

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis                                         

                8.1 Abbvie Inc.                 

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Pfizer Inc.                    

                8.3 AC Immune SA                          

                8.4 Eisai Co Ltd.                

                8.5 Allergan PLC                               

                8.6 Novartis AG                

                8.7 Amarantus Bioscience Holdings                         

                8.8 H. Lundbeck A/S                       

                8.9 Anavex LifeSciencescs                           

                8.10 Avid Radiopharmaceuticals                               

                8.11 Forest Laboratories Inc.                      

                8.12 Axon Neuroscience                              

                8.13 Daiichi Sankyo Co                   

                8.14 TauRx Therapeutics Ltd                       

                8.15 Eli Lilly                         

                8.16 F. Hoffmann La Roche AG                  

                8.17 Johnson & Johnson                              

                8.18 GE Healthcare                         

                8.19 Janssen Pharmaceuticals                    

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • The segment-level analysis in terms of Therapeutics, and Diagnostics along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global Alzheimer’s Disease Therapeutics and Diagnostics Market By Region, From 2019-2024 ( USD Billion )
  2. Global Alzheimer’s Disease Therapeutics and Diagnostics Market By Therapeutics, From 2019-2024 ( USD Billion )
  3. Global Marketed Drugs Market By Region, From 2019-2024 ( USD Billion )
  4. Global Pipeline Drugs Market By Region, From 2019-2024 ( USD Billion )
  5. Global Alzheimer’s Disease Therapeutics and Diagnostics Market By Diagnostics, From 2019-2024 ( USD Billion )
  6. Global Computed tomography scan Market By Region, From 2019-2024 ( USD Billion )
  7. Global Electroencephalography Market By Region, From 2019-2024 ( USD Billion )
  8. Global Lumbar puncture test Market By Region, From 2019-2024 ( USD Billion )
  9. Global Magnetic resonance imaging Market By Region, From 2019-2024 ( USD Billion )
  10. Global Positron emission tomography Market By Region, From 2019-2024 ( USD Billion )
  11. Global Other diagnostics Market By Region, From 2019-2024 ( USD Billion )
  12. Global Alzheimer’s Disease Therapeutics and Diagnostics Market By Marketed Drugs, From 2019-2024 ( USD Billion )
  13. Global NMDA Receptor Antagonists Market By Region, From 2019-2024 ( USD Billion )
  14. Global Cholinesterase Inhibitors Market By Region, From 2019-2024 ( USD Billion )
  15. North America Alzheimer’s Disease Therapeutics and Diagnostics Market By Therapeutics, From 2019-2024 ( USD Billion )
  16. North America Marketed Drugs Market By Region, From 2019-2024 ( USD Billion )
  17. North America Pipeline Drugs Market By Region, From 2019-2024 ( USD Billion )
  18. North America Alzheimer’s Disease Therapeutics and Diagnostics Market By Diagnostics, From 2019-2024 ( USD Billion )
  19. North America Computed tomography scan Market By Region, From 2019-2024 ( USD Billion )
  20. North America Electroencephalography Market By Region, From 2019-2024 ( USD Billion )
  21. North America Lumbar puncture test Market By Region, From 2019-2024 ( USD Billion )
  22. North America Magnetic resonance imaging Market By Region, From 2019-2024 ( USD Billion )
  23. North America Positron emission tomography Market By Region, From 2019-2024 ( USD Billion )
  24. North America Other diagnostics Market By Region, From 2019-2024 ( USD Billion )
  25. United States Alzheimer’s Disease Therapeutics and Diagnostics Market By Therapeutics, From 2019-2024 ( USD Billion )
  26. United States Alzheimer’s Disease Therapeutics and Diagnostics Market By Diagnostics, From 2019-2024 ( USD Billion )
  27. Canada Alzheimer’s Disease Therapeutics and Diagnostics Market By Therapeutics, From 2019-2024 ( USD Billion )
  28. Canada Alzheimer’s Disease Therapeutics and Diagnostics Market By Diagnostics, From 2019-2024 ( USD Billion )
  29. North America Alzheimer’s Disease Therapeutics and Diagnostics Market By Marketed Drugs, From 2019-2024 ( USD Billion )
  30. North America NMDA Receptor Antagonists Market By Region, From 2019-2024 ( USD Billion )
  31. North America Cholinesterase Inhibitors Market By Region, From 2019-2024 ( USD Billion )
  32. United States Alzheimer’s Disease Therapeutics and Diagnostics Market By Marketed Drugs, From 2019-2024 ( USD Billion )
  33. Canada Alzheimer’s Disease Therapeutics and Diagnostics Market By Marketed Drugs, From 2019-2024 ( USD Billion )
  34. Europe Alzheimer’s Disease Therapeutics and Diagnostics Market By Therapeutics, From 2019-2024 ( USD Billion )
  35. Europe Marketed Drugs Market By Region, From 2019-2024 ( USD Billion )
  36. Europe Pipeline Drugs Market By Region, From 2019-2024 ( USD Billion )
  37. Europe Alzheimer’s Disease Therapeutics and Diagnostics Market By Diagnostics, From 2019-2024 ( USD Billion )
  38. Europe Computed tomography scan Market By Region, From 2019-2024 ( USD Billion )
  39. Europe Electroencephalography Market By Region, From 2019-2024 ( USD Billion )
  40. Europe Lumbar puncture test Market By Region, From 2019-2024 ( USD Billion )
  41. Europe Magnetic resonance imaging Market By Region, From 2019-2024 ( USD Billion )
  42. Europe Positron emission tomography Market By Region, From 2019-2024 ( USD Billion )
  43. Europe Other diagnostics Market By Region, From 2019-2024 ( USD Billion )
  44. U.K. Alzheimer’s Disease Therapeutics and Diagnostics Market By Therapeutics, From 2019-2024 ( USD Billion )
  45. U.K. Alzheimer’s Disease Therapeutics and Diagnostics Market By Diagnostics, From 2019-2024 ( USD Billion )
  46. Germany Alzheimer’s Disease Therapeutics and Diagnostics Market By Therapeutics, From 2019-2024 ( USD Billion )
  47. Germany Alzheimer’s Disease Therapeutics and Diagnostics Market By Diagnostics, From 2019-2024 ( USD Billion )
  48. France Alzheimer’s Disease Therapeutics and Diagnostics Market By Therapeutics, From 2019-2024 ( USD Billion )
  49. France Alzheimer’s Disease Therapeutics and Diagnostics Market By Diagnostics, From 2019-2024 ( USD Billion )
  50. Italy Alzheimer’s Disease Therapeutics and Diagnostics Market By Therapeutics, From 2019-2024 ( USD Billion )
  51. Italy Alzheimer’s Disease Therapeutics and Diagnostics Market By Diagnostics, From 2019-2024 ( USD Billion )
  52. Spain Alzheimer’s Disease Therapeutics and Diagnostics Market By Therapeutics, From 2019-2024 ( USD Billion )
  53. Spain Alzheimer’s Disease Therapeutics and Diagnostics Market By Diagnostics, From 2019-2024 ( USD Billion )
  54. Europe Alzheimer’s Disease Therapeutics and Diagnostics Market By Marketed Drugs, From 2019-2024 ( USD Billion )
  55. Europe NMDA Receptor Antagonists Market By Region, From 2019-2024 ( USD Billion )
  56. Europe Cholinesterase Inhibitors Market By Region, From 2019-2024 ( USD Billion )
  57. U.K. Alzheimer’s Disease Therapeutics and Diagnostics Market By Marketed Drugs, From 2019-2024 ( USD Billion )
  58. Germany Alzheimer’s Disease Therapeutics and Diagnostics Market By Marketed Drugs, From 2019-2024 ( USD Billion )
  59. France Alzheimer’s Disease Therapeutics and Diagnostics Market By Marketed Drugs, From 2019-2024 ( USD Billion )
  60. Italy Alzheimer’s Disease Therapeutics and Diagnostics Market By Marketed Drugs, From 2019-2024 ( USD Billion )
  61. Spain Alzheimer’s Disease Therapeutics and Diagnostics Market By Marketed Drugs, From 2019-2024 ( USD Billion )
  62. Asia-Pacific Alzheimer’s Disease Therapeutics and Diagnostics Market By Therapeutics, From 2019-2024 ( USD Billion )
  63. Asia-Pacific Marketed Drugs Market By Region, From 2019-2024 ( USD Billion )
  64. Asia-Pacific Pipeline Drugs Market By Region, From 2019-2024 ( USD Billion )
  65. Asia-Pacific Alzheimer’s Disease Therapeutics and Diagnostics Market By Diagnostics, From 2019-2024 ( USD Billion )
  66. Asia-Pacific Computed tomography scan Market By Region, From 2019-2024 ( USD Billion )
  67. Asia-Pacific Electroencephalography Market By Region, From 2019-2024 ( USD Billion )
  68. Asia-Pacific Lumbar puncture test Market By Region, From 2019-2024 ( USD Billion )
  69. Asia-Pacific Magnetic resonance imaging Market By Region, From 2019-2024 ( USD Billion )
  70. Asia-Pacific Positron emission tomography Market By Region, From 2019-2024 ( USD Billion )
  71. Asia-Pacific Other diagnostics Market By Region, From 2019-2024 ( USD Billion )
  72. Japan Alzheimer’s Disease Therapeutics and Diagnostics Market By Therapeutics, From 2019-2024 ( USD Billion )
  73. Japan Alzheimer’s Disease Therapeutics and Diagnostics Market By Diagnostics, From 2019-2024 ( USD Billion )
  74. China Alzheimer’s Disease Therapeutics and Diagnostics Market By Therapeutics, From 2019-2024 ( USD Billion )
  75. China Alzheimer’s Disease Therapeutics and Diagnostics Market By Diagnostics, From 2019-2024 ( USD Billion )
  76. India Alzheimer’s Disease Therapeutics and Diagnostics Market By Therapeutics, From 2019-2024 ( USD Billion )
  77. India Alzheimer’s Disease Therapeutics and Diagnostics Market By Diagnostics, From 2019-2024 ( USD Billion )
  78. Australia Alzheimer’s Disease Therapeutics and Diagnostics Market By Therapeutics, From 2019-2024 ( USD Billion )
  79. Australia Alzheimer’s Disease Therapeutics and Diagnostics Market By Diagnostics, From 2019-2024 ( USD Billion )
  80. South Korea Alzheimer’s Disease Therapeutics and Diagnostics Market By Therapeutics, From 2019-2024 ( USD Billion )
  81. South Korea Alzheimer’s Disease Therapeutics and Diagnostics Market By Diagnostics, From 2019-2024 ( USD Billion )
  82. Asia-Pacific Alzheimer’s Disease Therapeutics and Diagnostics Market By Marketed Drugs, From 2019-2024 ( USD Billion )
  83. Asia-Pacific NMDA Receptor Antagonists Market By Region, From 2019-2024 ( USD Billion )
  84. Asia-Pacific Cholinesterase Inhibitors Market By Region, From 2019-2024 ( USD Billion )
  85. Japan Alzheimer’s Disease Therapeutics and Diagnostics Market By Marketed Drugs, From 2019-2024 ( USD Billion )
  86. China Alzheimer’s Disease Therapeutics and Diagnostics Market By Marketed Drugs, From 2019-2024 ( USD Billion )
  87. India Alzheimer’s Disease Therapeutics and Diagnostics Market By Marketed Drugs, From 2019-2024 ( USD Billion )
  88. Australia Alzheimer’s Disease Therapeutics and Diagnostics Market By Marketed Drugs, From 2019-2024 ( USD Billion )
  89. Latin America Alzheimer’s Disease Therapeutics and Diagnostics Market By Therapeutics, From 2019-2024 ( USD Billion )
  90. Latin America Marketed Drugs Market By Region, From 2019-2024 ( USD Billion )
  91. Latin America Pipeline Drugs Market By Region, From 2019-2024 ( USD Billion )
  92. Latin America Alzheimer’s Disease Therapeutics and Diagnostics Market By Diagnostics, From 2019-2024 ( USD Billion )
  93. Latin America Computed tomography scan Market By Region, From 2019-2024 ( USD Billion )
  94. Latin America Electroencephalography Market By Region, From 2019-2024 ( USD Billion )
  95. Latin America Lumbar puncture test Market By Region, From 2019-2024 ( USD Billion )
  96. Latin America Magnetic resonance imaging Market By Region, From 2019-2024 ( USD Billion )
  97. Latin America Positron emission tomography Market By Region, From 2019-2024 ( USD Billion )
  98. Latin America Other diagnostics Market By Region, From 2019-2024 ( USD Billion )
  99. Brazil Alzheimer’s Disease Therapeutics and Diagnostics Market By Therapeutics, From 2019-2024 ( USD Billion )
  100. Brazil Alzheimer’s Disease Therapeutics and Diagnostics Market By Diagnostics, From 2019-2024 ( USD Billion )
  101. Argentina Alzheimer’s Disease Therapeutics and Diagnostics Market By Therapeutics, From 2019-2024 ( USD Billion )
  102. Argentina Alzheimer’s Disease Therapeutics and Diagnostics Market By Diagnostics, From 2019-2024 ( USD Billion )
  103. Mexico Alzheimer’s Disease Therapeutics and Diagnostics Market By Therapeutics, From 2019-2024 ( USD Billion )
  104. Mexico Alzheimer’s Disease Therapeutics and Diagnostics Market By Diagnostics, From 2019-2024 ( USD Billion )
  105. Rest of Latin America Alzheimer’s Disease Therapeutics and Diagnostics Market By Therapeutics, From 2019-2024 ( USD Billion )
  106. Rest of Latin America Alzheimer’s Disease Therapeutics and Diagnostics Market By Diagnostics, From 2019-2024 ( USD Billion )
  107. Latin America Alzheimer’s Disease Therapeutics and Diagnostics Market By Marketed Drugs, From 2019-2024 ( USD Billion )
  108. Latin America NMDA Receptor Antagonists Market By Region, From 2019-2024 ( USD Billion )
  109. Latin America Cholinesterase Inhibitors Market By Region, From 2019-2024 ( USD Billion )
  110. Brazil Alzheimer’s Disease Therapeutics and Diagnostics Market By Marketed Drugs, From 2019-2024 ( USD Billion )
  111. Argentina Alzheimer’s Disease Therapeutics and Diagnostics Market By Marketed Drugs, From 2019-2024 ( USD Billion )
  112. Mexico Alzheimer’s Disease Therapeutics and Diagnostics Market By Marketed Drugs, From 2019-2024 ( USD Billion )
  113. Middle East & Africa Alzheimer’s Disease Therapeutics and Diagnostics Market By Therapeutics, From 2019-2024 ( USD Billion )
  114. Middle East & Africa Marketed Drugs Market By Region, From 2019-2024 ( USD Billion )
  115. Middle East & Africa Pipeline Drugs Market By Region, From 2019-2024 ( USD Billion )
  116. Middle East & Africa Alzheimer’s Disease Therapeutics and Diagnostics Market By Diagnostics, From 2019-2024 ( USD Billion )
  117. Middle East & Africa Computed tomography scan Market By Region, From 2019-2024 ( USD Billion )
  118. Middle East & Africa Electroencephalography Market By Region, From 2019-2024 ( USD Billion )
  119. Middle East & Africa Lumbar puncture test Market By Region, From 2019-2024 ( USD Billion )
  120. Middle East & Africa Magnetic resonance imaging Market By Region, From 2019-2024 ( USD Billion )
  121. Middle East & Africa Positron emission tomography Market By Region, From 2019-2024 ( USD Billion )
  122. Middle East & Africa Other diagnostics Market By Region, From 2019-2024 ( USD Billion )
  123. Middle East Alzheimer’s Disease Therapeutics and Diagnostics Market By Therapeutics, From 2019-2024 ( USD Billion )
  124. Middle East Alzheimer’s Disease Therapeutics and Diagnostics Market By Diagnostics, From 2019-2024 ( USD Billion )
  125. Africa Alzheimer’s Disease Therapeutics and Diagnostics Market By Therapeutics, From 2019-2024 ( USD Billion )
  126. Africa Alzheimer’s Disease Therapeutics and Diagnostics Market By Diagnostics, From 2019-2024 ( USD Billion )
  127. Middle East & Africa Alzheimer’s Disease Therapeutics and Diagnostics Market By Marketed Drugs, From 2019-2024 ( USD Billion )
  128. Middle East & Africa NMDA Receptor Antagonists Market By Region, From 2019-2024 ( USD Billion )
  129. Middle East & Africa Cholinesterase Inhibitors Market By Region, From 2019-2024 ( USD Billion )
  130. Middle East Alzheimer’s Disease Therapeutics and Diagnostics Market By Marketed Drugs, From 2019-2024 ( USD Billion )
  131. Africa Alzheimer’s Disease Therapeutics and Diagnostics Market By Marketed Drugs, From 2019-2024 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample